สถาบันวิจัยวิทยาศาสตร์สาธารณสุข

National Institute of Health of Thailand

Authors : Nongluk Buddhirakkul*, Prayute Buddhirakkul**, Chaivat Kittigul***,Kruavon Balachadra*, Duanthanorm Thawaranantha*


Affiliations:        *National Institute of Health, Department of Medical Sciences,

Tiwanond Road, Nonthaburi,11000

**Faculty of Public Health, Mahidol University, Ratvithi Road,

Bangkok 10400

***Faculty of Sciences, Kasetsart University, Paholyothin Road,

Bangkok 10900

 

Source:            Bulletin of Department of Medical Sciences 1999; 42(4): 364-370  

 

Language:       Thai with English abstract

 

Abstract:

 

Dot ELISA assay for screening of Hepatitis B surface antigen (HBsAg) in human sera has been developed by using monoclonal antibody to HBsAg as probe. Monoclonal antibody raised against the common a antigenic determinant of HBsAg was obtained in our laboratory by fusion of myeloma cell line (P3-X63-Ag8.653) and spleen cells of BALB/c mice immunized with plasma derived hepatitis B virus vaccine (adr subtype). Four hundred serum samples were examined by both commercial ELISA kit and Dot ELISA test. Comparison results showed that 194 samples were positive by Dot ELISA test and 200 samples were positive by commercial ELISA kit. From these 200 samples, 188 of them were positive by both ELISA kit and Dot ELISA test, while the sensitivity and specificity were 94% and 97% respectively. The positive and negative predictive value were 97% and 94%. Based on the comparison results, the simplicity of performance and the economical nature of the test system, Dot ELISA could be used as a convenient and economical screening test which would be the advantageous test for small laboratories especially in developing countries.